Combinatorial targeting and discovery of ligand-receptors in organelles of mammalian cells
2012 · Nature Communications · 46 citations
https://doi.org/10.1038/ncomms1773
H
Hitomi Hosoya
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
105
Papers
1.3K
Citations
16
h-index
22
i10-index
Hitomi Hosoya is an academic researcher from Stanford Blood Center. The author has contributed to research in topics: CAR-T cell therapy research & Multiple Myeloma Research and Treatments & Protein Degradation and Inhibitors. The author has an h-index of 16, co-authored 90 publications.
ORCID: 0000-0003-0475-9666Papers by this author
worksBendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
2023 · Blood Cancer Journal · 32 citations
https://doi.org/10.1038/s41408-023-00929-0
Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma
2025 · Nature Communications · 9 citations
https://doi.org/10.1038/s41467-025-56486-6
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
2025 · Blood Cancer Journal · 7 citations
https://doi.org/10.1038/s41408-025-01314-9
MM-1395: Immune Reconstitution, Vaccine Protection, and Infectious Complications Following BCMA-Targeted CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
2025 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(25)02731-4
Rapid Peak CAR-T Expansion is Associated with Delayed Neurotoxicity Following Ciltacabtagene Autoleucel in Multiple Myeloma
2025 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(25)03409-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat